These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 32343679

  • 1. Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity.
    Wang J, Huang F, Jiang C, Chi P.
    Med Sci Monit; 2020 Apr 28; 26():e915854. PubMed ID: 32343679
    [Abstract] [Full Text] [Related]

  • 2. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
    He J, Zhang W, Di T, Meng J, Qi Y, Li G, Zhang Y, Su H, Yan W.
    Biomed Pharmacother; 2020 Nov 28; 131():110541. PubMed ID: 33152901
    [Abstract] [Full Text] [Related]

  • 3. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, Yin J, Zhu J, Zhong C.
    J Exp Clin Cancer Res; 2021 Aug 24; 40(1):266. PubMed ID: 34429133
    [Abstract] [Full Text] [Related]

  • 4. STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses.
    Jahangiri A, Dadmanesh M, Ghorban K.
    J Cell Physiol; 2020 Dec 24; 235(12):9457-9463. PubMed ID: 32401358
    [Abstract] [Full Text] [Related]

  • 5. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z, Liang M, Shang L, Lai M, Deng X, Su X.
    Pancreatology; 2021 Apr 24; 21(3):630-641. PubMed ID: 33707115
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.
    Lee JH, Lee DY, Lee HJ, Im E, Sim DY, Park JE, Park WY, Shim BS, Kim SH.
    Cells; 2021 Aug 20; 10(8):. PubMed ID: 34440920
    [Abstract] [Full Text] [Related]

  • 7. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX, Jin Y, Wang Z, Li MY, Zhang ZH, Wang JY, Xing Y, Ri MH, Jin CH, Xu GH, Piao LX, Ma J, Jin X.
    J Ethnopharmacol; 2020 Jul 15; 257():112835. PubMed ID: 32278762
    [Abstract] [Full Text] [Related]

  • 8. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H.
    Theranostics; 2020 Jul 15; 10(3):1033-1045. PubMed ID: 31938049
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H, Liu P, Zhang Y, Han L, Hu Z, Cai Z, Cai J.
    FEBS Open Bio; 2021 Mar 15; 11(3):911-920. PubMed ID: 33455075
    [Abstract] [Full Text] [Related]

  • 10. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang B, Fan P, Liu Z, Jin X, Wu H.
    J Exp Clin Cancer Res; 2019 Dec 09; 38(1):485. PubMed ID: 31818309
    [Abstract] [Full Text] [Related]

  • 11. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z, Sun H, Zhang Z, Zheng Y, Zheng S, Bin J, Liao Y, Shi M, Zhou R, Liao W.
    Cancer Commun (Lond); 2023 May 09; 43(5):562-581. PubMed ID: 37031362
    [Abstract] [Full Text] [Related]

  • 12. LRP8 activates STAT3 to induce PD-L1 expression in osteosarcoma.
    Zheng S, Wei Y, Jiang Y, Hao Y.
    Tumori; 2021 Jun 09; 107(3):238-246. PubMed ID: 33054597
    [Abstract] [Full Text] [Related]

  • 13. RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
    Ganesh S, Kim MJ, Lee J, Feng X, Ule K, Mahan A, Krishnan HS, Wang Z, Anzahaee MY, Singhal G, Korboukh I, Lockridge JA, Sanftner L, Rijnbrand R, Abrams M, Brown BD.
    Mol Ther; 2024 Jun 05; 32(6):1895-1916. PubMed ID: 38549376
    [Abstract] [Full Text] [Related]

  • 14. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation.
    Wang JY, Jiang MW, Li MY, Zhang ZH, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Jin HL, Ma J, Jin Y, Zuo HX, Jin X.
    J Nutr Biochem; 2022 Feb 05; 100():108899. PubMed ID: 34748924
    [Abstract] [Full Text] [Related]

  • 15. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, Larrick JW, Hu MC.
    J Immunother Cancer; 2021 Dec 05; 9(12):. PubMed ID: 34887262
    [Abstract] [Full Text] [Related]

  • 16. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
    Gao W, Wen H, Liang L, Dong X, Du R, Zhou W, Zhang X, Zhang C, Xiang R, Li N.
    Theranostics; 2021 Dec 05; 11(6):2564-2580. PubMed ID: 33456560
    [Abstract] [Full Text] [Related]

  • 17. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM, Qian XL, Xia XQ, Li YQ, Sun YY, Jia YM, Wang J, Xue HQ, Gao GS, Wang XZ, Zhang XM, Guo XJ.
    Breast Cancer Res Treat; 2022 Nov 05; 196(1):45-56. PubMed ID: 36056297
    [Abstract] [Full Text] [Related]

  • 18. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M, Yamamoto J, Ito T, Handa H, Sunakawa-Kii M, Inokuchi K, Morita R, Tamura H.
    Mol Cancer Ther; 2021 Jul 05; 20(7):1283-1294. PubMed ID: 33879556
    [Abstract] [Full Text] [Related]

  • 19. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E, Rasmi Y, Baradaran B.
    J Cell Physiol; 2021 Oct 05; 236(10):7071-7087. PubMed ID: 33821473
    [Abstract] [Full Text] [Related]

  • 20. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion.
    Fang W, Zhou T, Shi H, Yao M, Zhang D, Qian H, Zeng Q, Wang Y, Jin F, Chai C, Chen T.
    J Exp Clin Cancer Res; 2021 Jan 04; 40(1):4. PubMed ID: 33390170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.